CVKD

NASDAQ 已收盘

Cadrenal Therapeutics

1.70 USD
▲+0.01+0.59%
盘后 1.61 -5.29%
2026-11-20
市值
$6.06M
市盈率
—
EPS
-3.51
股息率
—
52 周区间
0.82 – 12.50
成交量
206.73K
Beta
1.96
目标价
14.00
52W 低 0.8252W 高 12.50
价格走势

公司简介

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatm...